EUVIMEDEUVIMED entdecken
Fallbericht

Results of esketamine administration in a Greek population; a case series

Petros Fotiadis, Eleni Tsalkitzi, Dimos Dimellis, Konstantinos Rantis, Athanasios Tsimpiris, Georgios Pagkalos

Psychiatriki · 2024

DOI: 10.22365/jpsych.2024.006 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Psychiatriki, 2024. Verfasst von Petros Fotiadis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Outpatient Psychiatric Department, 424 Military Hospital of Thessaloniki, Greece. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Administration, Intranasal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esketamine is a non-selective, competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor in the brain. Through NMDA receptor antagonism, esketamine causes a transient increase in glutamate release, leading to increases in neurotrophic signaling and restoration of synaptic function in brain regions involved in mood regulation and emotional behavior. Several randomized clinical trials have shown its effectiveness in reducing the symptoms of depression in some people, despite its short-term side effects that include mainly disorientation, dizziness, nausea, and increased blood pressure. In 2019, the United States Food and Drug Administration (FDA) as well as the European Medicines Agency approved the use of esketamine nasal spray in combination with an oral antidepressant for treatment-resistant depression in adults. Our study aimed to evaluate the effectiveness of this new therapeutic proposal in a case series of five Greek patients with treatment- resistant depression. Intranasal esketamine was administered under medical supervision in combination with an oral antidepressant. Depressive symptoms were evaluated at three time points (baseline, end of treatment, and one-year post-treatment) using the Montgomery-Åsberg Depression Rating Scale (MADRS), the Patient Health Questionnaire (PHQ-9), the CGI Clinical Global Impression Scale, and the Perceived Deficits Questionnaire for Depression (PDQ-D). Possible side effects were assessed using the Richmond Suppression Agitation Scale (RASS), the Sheehan Disability Scale (SDS), the CADSS Disruptive States Scale, and a predefined list of adverse events (AEs) and serious adverse events (SAEs). Patients followed an individualized treatment plan for seven to twelve months depending on the achievement of an adequate response. Statistical analysis of the results revealed a significant improvement (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDepressive Disorder, Treatment-ResistantAdministration, IntranasalHumansMaleFemaleMiddle AgedAdultGreeceAntidepressive AgentsTreatment OutcomeDrug Therapy, CombinationPsychiatric Status Rating Scales

Stichwörter der Autor:innen

Esketaminefast-acting antidepressantmood disorderstherapeutic interventiontreatment-resistant depression

Substanzen

KetamineEsketamineAntidepressive Agents

Autor:innen und Institutionen

  • Outpatient Psychiatric Department, 424 Military Hospital of Thessaloniki, Greece.
  • Dental Department, 424 Military Hospital of Thessaloniki, Greece.

Zitieren

APA

Fotiadis, P., Tsalkitzi, E., Dimellis, D., Rantis, K., Tsimpiris, A., & Pagkalos, G. (2024). Results of esketamine administration in a Greek population; a case series. Psychiatriki. https://doi.org/10.22365/jpsych.2024.006

Vancouver

Fotiadis P, Tsalkitzi E, Dimellis D, Rantis K, Tsimpiris A, Pagkalos G. Results of esketamine administration in a Greek population; a case series. Psychiatriki. 2024. doi:10.22365/jpsych.2024.006

BibTeX
@article{Fotiadis2024,
  author = {Fotiadis, Petros and Tsalkitzi, Eleni and Dimellis, Dimos and Rantis, Konstantinos and Tsimpiris, Athanasios and Pagkalos, Georgios},
  title = {Results of esketamine administration in a Greek population; a case series},
  journal = {Psychiatriki},
  year = {2024},
  doi = {10.22365/jpsych.2024.006}
}
Kostenlos starten →